Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96HJ3
UPID:
CCD34_HUMAN
Alternative names:
Renal carcinoma antigen NY-REN-41
Alternative UPACC:
Q96HJ3; B2R8G2; Q8IX69; Q9H2A6; Q9Y599
Background:
Coiled-coil domain-containing protein 34, also known as Renal carcinoma antigen NY-REN-41, plays a crucial role in spermatogenesis. It is specifically involved in anterograde intraflagellar transport, a process vital for the formation of sperm flagella. This protein's function underscores its importance in the reproductive system, particularly in the development of spermatozoa.
Therapeutic significance:
Spermatogenic failure 76, a male infertility disorder characterized by oligoasthenoteratozoospermia and abnormally shaped spermatozoa, is associated with mutations affecting this protein. Understanding the role of Coiled-coil domain-containing protein 34 could open doors to potential therapeutic strategies for treating this infertility disorder.